Literature DB >> 19115427

The voice and you: development and psychometric evaluation of a measure of relationships with voices.

Mark Hayward1, Joanna Denney, Sam Vaughan, David Fowler.   

Abstract

The experience of hearing voices has recently been conceptualized within a relational framework. Birtchnell's Relating Theory offers a framework capable of exploring the power and intimacy within the relationship between the hearer and the voice. However, measures of relationships with voices derived from the theory, such as the Hearer to Voice (HTV) and Voice to Hearer (VTH) by Vaughan and Fowler, have lacked robust psychometric properties. Data were available from 71 participants who completed the HTV and VTH, and analysis of these data generated a new 29-item measure, the Voice and You (VAY), capable of assessing the 'interrelating' between the hearer and the voice. The VAY was completed by a further 30 participants and was found to be internally consistent, stable over time and associated with other measures of the voice-hearing experience. The VAY offers a psychometrically stable measure of the relationship between the hearer and the voice. It may be used as an adjunct to the clinical interview and/or a measure of outcome. Copyright (c) 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2008        PMID: 19115427     DOI: 10.1002/cpp.561

Source DB:  PubMed          Journal:  Clin Psychol Psychother        ISSN: 1063-3995


  8 in total

1.  Smartphone-assisted guided self-help cognitive behavioral therapy for young people with distressing voices (SmartVoices): study protocol for a randomized controlled trial.

Authors:  Marialuisa Cavelti; Janko M Kaeser; Stefan Lerch; Stephanie Bauer; Markus Moessner; Thomas Berger; Mark Hayward; Michael Kaess
Journal:  Trials       Date:  2022-10-23       Impact factor: 2.728

2.  The psychometric properties of the DAIMON Scale, a translation from Spanish to English: An instrument to measure the relationship with and between voices.

Authors:  Cherise Rosen; Kayla A Chase; Salvador Perona-Garcelán; Robert W Marvin; Rajiv P Sharma
Journal:  Psychosis       Date:  2019-09-02

3.  Relating therapy for voices (the R2V study): study protocol for a pilot randomized controlled trial.

Authors:  Mark Hayward; Clara Strauss; Leanne Bogen-Johnston
Journal:  Trials       Date:  2014-08-16       Impact factor: 2.279

4.  Establishing the "Fit" between the Patient and the Therapy: The Role of Patient Gender in Selecting Psychological Therapy for Distressing Voices.

Authors:  Mark Hayward; Luke Slater; Katherine Berry; Salvador Perona-Garcelán
Journal:  Front Psychol       Date:  2016-03-31

5.  On shame and voice-hearing.

Authors:  Angela Woods
Journal:  Med Humanit       Date:  2017-04-07

6.  Symptom dimensions of the psychotic symptom rating scales in psychosis: a multisite study.

Authors:  Todd S Woodward; Kwanghee Jung; Heungsun Hwang; John Yin; Laura Taylor; Mahesh Menon; Emmanuelle Peters; Elizabeth Kuipers; Flavie Waters; Tania Lecomte; Iris E Sommer; Kirstin Daalman; Remko van Lutterveld; Daniela Hubl; Jochen Kindler; Philipp Homan; Johanna C Badcock; Saruchi Chhabra; Matteo Cella; Sarah Keedy; Paul Allen; Andrea Mechelli; Antonio Preti; Sara Siddi; David Erickson
Journal:  Schizophr Bull       Date:  2014-07       Impact factor: 9.306

7.  Guided self-help cognitive behavioral intervention for VoicEs (GiVE): study protocol for a pilot randomized controlled trial.

Authors:  Cassie M Hazell; Mark Hayward; Kate Cavanagh; Anna-Marie Jones; Clara Strauss
Journal:  Trials       Date:  2016-07-26       Impact factor: 2.279

8.  Increasing access to CBT for psychosis patients: a feasibility, randomised controlled trial evaluating brief, targeted CBT for distressing voices delivered by assistant psychologists (GiVE2).

Authors:  Mark Hayward; Clio Berry; Ben Cameron; Kate Arnold; Katherine Berry; Stephen Bremner; Kate Cavanagh; David Fowler; Heather Gage; Kathryn Greenwood; Cassie Hazell; Anna-Marie Jones; Sam Robertson; Clara Strauss
Journal:  Trials       Date:  2020-04-01       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.